Ropes & Gray Advises Aptalis and TPG in $2.9 Billion Cash Sale

In The News
January 8, 2014

Ropes & Gray advised Aptalis, a privately held specialty pharmaceutical company, in its definitive agreement to be acquired by Forest Laboratories, Inc., also a specialty pharmaceutical company. Forest Laboratories has agreed to acquire Aptalis for $2.9 billion in cash from its shareholders, including TPG, a global private investment firm.

The Ropes & Gray team was led by private equity transactions partners William Shields and Michael Roh and included securities & shareholder litigation partner Patrick O’Brien, benefits partner Loretta Richard, tax partner Elaine Murphy, antitrust partner Michael McFalls, and finance partner Alexander Zeltser.